Abstract:Objective To explore the diagnostic value of human papillomavirus (HPV) E6/E7 mRNA in cervical lesions screening.Methods From December 2016 to May 2017 in the department of obstetrics and gynecology of Xijing Hospital, we collected 163 women who were screened for cervical lesion in the combined test of cytology and HPV DNA genotyping, then conducted transvaginal biopsy. Meanwhile all patients were detected through HPV E6/E7 mRNA testing, and the cervical biopsy pathological diagnosis was used as the gold standard. We compared HPV E6/E7 mRNA, cytology, and HPV DNA genotyping to detect CINII+ in the indicators of sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, and area under the receiver operating characteristic curve (AUC). We also compared the ability of three methods to detect cervical lesion, and the relationship between HPV E6/E7 mRNA expression level and pathological grades.Results The results of indicators of HPV E6/E7 mRNA, HPV DNA genotyping and cytological test for screening cervical lesion CINII+ were as follows: The sensitivities were 86.8%, 88.7% and 88.7%; The specificities were 71.8%, 19.1% and 43.6%; The positive predictive values were 59.7%, 34.6% and 43.1%; The negative predictive values were 91.8 %, 77.8% and 88.8%; The positive likelihood values were 3.1, 1.1 and 1.6; The negative likelihood values were 0.2, 0.6 and 0.3; The AUC were 0.793, 0.539 and 0.662, respectively. Diagnostic performance of HPV E6/E7 mRNA was higher than that of HPV DNA genotyping and cytological test. There was statistical significance between different pathological grades and HPV E6/E7 mRNA expression levels (P<0.01), and HPV E6/E7 mRNA expression levels were positively correlated to cervical lesion grads (P<0.05).Conclusion HPV E6/E7 mRNA has clinical significance for the diagnosis of cervical lesion, and clinicians should pay attention to it.
苏瑛, 范小斌, 罗天爱, 谢婷婷, 于月成. HPV E6/E7mRNA在宫颈病变检测中的诊断价值[J]. 中国生育健康杂志, 2018, 29(6): 506-510.
SU Ying, FAN Xiaobin, LUO Tianai, XIE Tingting, YU Yuecheng. Diagnostic value of human papillomavirus E6/E7 mRNA in the detection of cervical lesions. Chinese Journal of Reproductive Health, 2018, 29(6): 506-510.
1 Plummer M,de Martel C,Vignat J,et al.Global burden of cancers attributable to infections in 2012:a synthetic analysis.Lancet Glob Health,2016,4:e609-e616.
2 Graham SV,Faizo AA.Control of human papillomavirus gene expression by alternative splicing.Virus Res,2017,231:83-95.
3 Ganguly N,Parihar SP.Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis.J Biosci,2009,34:113-123.
4 Nakagawa S,Yoshikawa H,Yasugi T,et al.Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type.J Med Virol,2000,62:251-258.
5 Carter JR,Ding Z,Rose BR.HPV infection and cervical disease:a review.Aust N Z J Obstet Gynaecol,2011,51:103-108.
6 Zhao X,Cui Y,Jiang S,et al.Comparative study of HR HPV E6/E7 mRNA and HR-HPV DNA in cervical cancer screening.Zhonghua Yi Xue Za Zhi,2014,94:3432-3435.
7 Maggino T,Sciarrone R,Murer B,et al.Screening women for cervical cancer carcinoma with a HPV mRNA test:first results from the Venice pilot program.Br J Cancer,2016,115:525-532.
8 Reid JL,Wright TJ,Stoler MH,et al.Human papillomavirus oncogenic mRNA testing for cervical cancer screening:baseline and longitudinal results from the CLEAR study.Am J Clin Pathol,2015,144:473-483.
9 Nayar R,Wilbur DC.The Bethesda System for Reporting Cervical Cytology:A Historical Perspective.Acta Cytol,2017,61:359-372.
10 孙振球,主编.医学统计学.第四版.北京:人民卫生出版社,2014:597-601.
11 Plummer M,Schiffman M,Castle PE,et al.A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesionJ.J Infect Dis,2007,195:1582-1589.
12 Naucler P,Ryd W,Tornberg S,et al.Human papillomavirus and Papanicolaou tests to screen for cervical cancer.N Engl J Med,2007,357:1589-1597.
13 Practice Bulletin No.168 Summary:Cervical Cancer Screening and Prevention.Obstet Gynecol,2016,128:923-925.
14 Iftner T,Becker S,Neis KJ,et al.Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.J Clin Microbiol,2015,53:2509-2516.
15 Ge Y,Christensen P,Luna E,et al.Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.Cancer,2017,125:652-657.
16 Ren C,Zhu Y,Yang L,et al.Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears.Arch Gynecol Obstet,2017,297:425-432.
17 Szarewski A,Mesher D,Cadman L,et al.Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears:the Predictors 2 study.J Clin Microbiol,2012,50:1867-1873.
18 Castle PE,Eaton B,Reid J,et al.Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.J Clin Microbiol,2015,53:1277-1281.
19 Haedicke J,Iftner T.A review of the clinical performance of the Aptima HPV assay.J Clin Virol,2016,76 Suppl 1:S40-S48.